诺和诺德昨日在印度推出减肥药Wegovy，较原定2026年推出的计划提早一年。此次推出涵盖五种不同剂量，价格从每周约4366卢比(约合50美元)的0.25毫克剂量，到每周约6503卢比的2.4毫克剂量，显著低于美国2.4毫克每周337美元的价格。作为对比，礼来Mounjaro的2.5毫克剂量的价格约约为每周3500卢比。另据彭博报道，Mounjaro在印度5月销售额按月增长60%，达到1.26亿卢比(约合146.6万美元)。据医学期刊的研究报告，印度的肥胖人口预计将从2021年的1.8亿增加到2050年的4.5亿，成为仅次于中国的全球第二大肥胖市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.